Study of ipratropium bromide inhalation in stable asthma.

Ailani, R K; Shah, S P; Koyande, D; Kudalkar, S S; Kodge, K; Deshmukh, Y A

Ailani, R K; Shah, S P; Koyande, D; Kudalkar, S S; Kodge, K; Deshmukh, Y A.

Article in English | IMSEAR | ID: sea-85322

ABSTRACT

ABSTRACT

An open two weeks short term trial of Ipratropium Bromide (IB) inhalation (0.02 mg per dose) was carried out in 20 stable asthamatics to study its efficacy and safety. Early significant rise in PEFR (P < 0.001) and FEV1 (P < 0.05) was observed after 15 min of IB inhalation and reached significant peak (P < 0.01) after 1 hour which was persistent beyond three hours after IB inhalation. No side effects were observed. It was concluded that Ipratropium Bromide Imhalation is safe and has efficient bronchodilatory effect on short term basis in stable asthmatics.

Subject(s)

Administration, Inhalation; Adolescent; Adult; Asthma/prevention & control; Bronchodilator Agents/administration & dosage; Electrocardiography/drug effects; Female; Follow-Up Studies; Forced Expiratory Volume/drug effects; Humans; Ipratropium/administration & dosage; Male; Peak Expiratory Flow Rate/drug effects; Safety; Time Factors; Vital Capacity/drug effects

Fulltext

XML

Search on Google

Full text: Available Index: IMSEAR (South-East Asia) Main subject: Asthma / Safety / Time Factors / Administration, Inhalation / Bronchodilator Agents / Female / Humans / Male / Peak Expiratory Flow Rate / Vital Capacity Type of study: Observational study / Prognostic study Language: English Year: 1995 Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

Search on Google